SYRE · Spyre Therapeutics, Inc. · Stock research

Current Thesis

The date ambiguity is gone. Third-party trackers had the Q2 report at 2026-08-06 or 2026-08-14; it landed pre-market on 2026-08-04, and it carried the one thing the pipeline had withheld since the 2026-05-05 corporate update. Both remaining 2026 monotherapy readouts — SPY003 (anti-IL-23) SKYLINE Part A induction topline and the SPY072 (anti-TL1A) SKYWAY rheumatoid-arthritis sub-study — moved from "Q3 2026" to September 2026, on the release and on spyre.com/pipeline. Psoriatic arthritis and axial spondyloarthritis stay in Q4 2026; SKYLINE Part B combination induction data stay in 2027.

The tape took it. SYRE closed 2026-08-04 at $104.94, up 10.54% ($10.01) after opening $98.27 and trading $97.03–$105.25 — a new 52-week and all-time intraday high, eclipsing the $105.05 printed 2026-07-27. That resolves the three-week coil between $92.37 (2026-07-28 low) and $105.25 upward.

The narrative leg being bought: a platform that has cleared two of three monotherapy proof-of-concept shots now hands over a dated month for the third, plus its first placebo-controlled efficacy readout, with financing pressure absent. Cameron Turtle attached a timeline to the rheumatology arm for the first time on 2026-08-04 — "if successful, we look forward to initiating pivotal development of SPY072 next year."

One line of the print deserves care. The headline EPS of −$0.36 against consensus near −$0.73 to −$0.75 was not an operating result. Q2 net loss of $36.2M includes a $40.0M gain on the sale of an in-process R&D asset — Immedica's monetization of a priority review voucher tied to the legacy pegzilarginase rights sold in 2023. Strip it and R&D was $65.5M (versus $40.1M in Q2 2025), G&A $16.1M (versus $11.8M), and operating cash use $69.9M.

Life-cycle: MATURING. Dating it: the price high is new, the participation behind it is not. The 2026-08-04 breakout traded 831,929 shares against a 20-day average of 1,066,067 — the fourth straight session under 900,000, after 1,513,005 on 2026-07-28 and 1,216,609 on 2026-07-29. Sell-side response to the print was one maintenance note (LifeSci Capital, Buy, $119, 2026-08-04), not a fresh wave; the roster is unchanged at 17 analysts, 16 strong buy and one hold since Wolfe Research moved to Peer Perform on 2026-07-28. The $105.79 average target now sits $0.85 above the closing price. Short interest fell to 12.51M shares at the 2026-07-31 settlement from 13.64M a month earlier. The story is working and well known; the marginal bid is not widening.

Bullish and bearish views on Spyre Therapeutics, Inc.

The model's bull view on Spyre Therapeutics, Inc. (SYRE), in brief: Two of three shots cleared, restated without revision on 2026-08-04. The bear view: The earnings beat was non-operating. The $40.0M IPR&D gain carried the −$0.36 print. Operating expense ran $81.6M in the quarter against $51.9M a year earlier, and operating cash use was $69.9M. Every efficacy number in hand is open-label. SKYLINE Part A is a single-dose… Both cases follow in full.

Bull Case

• Two of three shots cleared, restated without revision on 2026-08-04. SPY001 Part A (announced 2026-04-13): Robart's Histopathology Index −9.2 (p<0.0001), clinical remission 40%, endoscopic improvement 51%. SPY002 Part A (2026-06-15): RHI −10.7 (p<0.0001), clinical remission 33%, endoscopic improvement 42%. Modified Mayo Score change −3.7 for both.
• The Q3 window narrowed to a month. SPY003 Part A and the SKYWAY RA sub-study both guided to September 2026 on the 2026-08-04 release and the live pipeline page; the company restated it is "on track for 6 proof-of-concept Phase 2 readouts in 2026."
• Balance sheet is not the constraint. $1,145.3M in cash, equivalents and marketable securities at 2026-06-30 ($162.0M cash plus $983.3M marketable securities), including $435.2M net from the April 2026 follow-on. Runway guided into 2H 2029.
• Enrollment ran ahead of plan. All three SKYWAY sub-studies over-enrolled on or ahead of schedule (completion announced 2026-06-03, reiterated 2026-08-04), which is why September is now a month rather than a quarter.
• The target itself cleared Phase 3. Merck's tulisokibart met the primary endpoint of week-12 clinical remission in ATLAS-UC Study 2 on 2026-06-22 — the first anti-TL1A antibody through Phase 3 in ulcerative colitis, on the mechanism SPY002 and SPY072 both use.
• A pivotal timeline exists now. Management's 2026-08-04 statement points to initiating pivotal SPY072 development in 2027 contingent on the RA read, and to combination work outside IBD.

Bear Case

• The earnings beat was non-operating. The $40.0M IPR&D gain carried the −$0.36 print. Operating expense ran $81.6M in the quarter against $51.9M a year earlier, and operating cash use was $69.9M.
• Every efficacy number in hand is open-label. SKYLINE Part A is a single-dose, single-arm monotherapy assessment with no placebo control, per the company's own description. SPY003 in September is the same design. The SKYWAY RA sub-study — double-blind, placebo-controlled, two dose levels, week 12 — is the first placebo-controlled efficacy readout either trial produces, and open-label effect sizes have a long history of compressing against a placebo arm.
• Price has caught the consensus. $104.94 close versus a $105.79 average target across 17 analysts, range $88 to $135. Wolfe's 2026-07-28 downgrade put standalone fair value at $96–$113 against a $165 takeout scenario, so the close sits inside the skeptic's standalone band.
• Undrawn issuance capacity is larger than previously visible. The 2024 $200M sales agreement was terminated 2026-06-26 and replaced the same day with a 2026 sales agreement with TD Securities for up to $500.0M of common stock. Nothing was sold under it through 2026-06-30. It remains live at a record price.
• Preferred overhang unchanged. 346,045 Series A shares were outstanding at 2026-06-30, convertible into 13,841,800 common, against 88,064,133 common shares outstanding (78,189,811 at 2025-12-31).

• Three anti-TL1A antibodies are already in Phase 3 — Merck tulisokibart, Roche/Genentech afimkibart, Sanofi/Teva duvakitug — while Spyre's most advanced asset is in Phase 2 Part B.

Setup & Price Structure

2026-08-04 close $104.94 (+10.54%), session range $97.03–$105.25, volume 831,929. The prior five sessions: $94.93 (−3.46%, 898,396), $98.33 (−3.12%, 621,726), $101.50 (+3.71%, 851,502), $97.87 (−2.09%, 1,216,609), $99.96 (−0.08%, 1,513,005). Price entered the print at the floor of its range and exited at the ceiling.

The consolidation that resolved runs 2026-07-20 to 2026-08-04: high $105.25, low $92.37 (2026-07-28 intraday), with a second test at $92.71 on 2026-08-03. That $92 shelf is the structure the breakout is standing on.

Trend backdrop: 50-day average $88.73 and rising, 200-day average $53.17. The 52-week range is $14.51–$105.25, a 545% 52-week change. Float 82.07M of 87.94M shares outstanding, institutional ownership 91.28%, beta 3.03, short interest 12.51M shares or 15.24% of float at the 2026-07-31 settlement with 6.57 days to cover.

Crowding observables, stated without a verdict: coverage is 16 strong buy against one hold; the closing price is within a dollar of the 17-analyst average target; the breakout session traded 78% of the 20-day average volume; short interest has been falling for a month rather than building; an officer 144 was filed the day before the print; and $500M of at-the-market capacity sits registered and undrawn at an all-time high.

Catalyst Calendar (next 30 days)

• ~2026-09-15 (est., no fixed date) — SPY072 SKYWAY rheumatoid-arthritis sub-study topline. Guided to September 2026. Double-blind, placebo-controlled, two dose levels at week 12 with open-label follow-up through week 36.
• ~2026-09-15 (est., no fixed date) — SPY003 SKYLINE Part A induction topline. Guided to September 2026. Open-label, single dose level.
• ~2026-08-25 (est.) — short interest settlement data for the 2026-08-14 settlement date publishes, the first positioning read that spans the print.

Nothing on this list is a confirmed calendar date inside the next 30 days. The company has fixed a month, not a day, for both September readouts, and has issued no scheduling release for either.

Elapsed catalysts

• 2026-08-04 — ELAPSED. Q2 2026 results and corporate update (8-K Item 2.02, Exhibit 99.1). Delivered the September guidance narrowing, the $1,145.3M cash figure, and confirmation of no Q2 ATM draw. The release carried no conference-call detail. (passed 5d ago)

What Would Change Our Mind

September is now the whole argument. If the month closes with either SPY003 Part A or the SKYWAY RA sub-study still undelivered — or with the pipeline page carrying Q4 2026 where it now says September — the guidance narrowing that produced the 2026-08-04 breakout has been withdrawn, and the reason price sits at the $105.79 consensus goes with it.

The second break is scientific rather than procedural: the RA sub-study is placebo-controlled, and a placebo-adjusted result materially thinner than the open-label Part A effect sizes would say the monotherapy numbers do not survive a control arm. That reads directly across to SPY002 and to the 2027 combination data the $115–$135 targets are built on.

On the tape, a weekly close below $92 surrenders the 2026-07-20 to 2026-08-04 consolidation floor that the print broke out of ($92.37 intraday 2026-07-28, $92.71 on 2026-08-03), which would place the breakout inside the range that preceded it. Confirming evidence for the crowding read would be shares appearing under the 2026 sales agreement in the Q3 10-Q, a second and third firm joining Wolfe at hold, or the average target drifting toward the $96–$113 standalone band rather than upward after the September prints.

Correlation Notes

• Anti-TL1A class beta. SYRE moves on other companies' data. Merck (tulisokibart), Roche/Genentech (afimkibart) and Sanofi/Teva (duvakitug) all read across; the 2026-06-22 ATLAS-UC Study 2 win was a Merck release that revalidated a Spyre mechanism. Full placebo-adjusted ATLAS-UC numbers at a scientific congress become the benchmark against which SPY002's open-label 33% remission is judged.
• Rate and risk-appetite beta. At 3.03 beta with no revenue and no approved product, valuation is a duration asset. Broad biotech drawdowns move this name more than the mechanism news does on quiet weeks.
• Related-party complex. All four antibodies are licensed from Paragon Therapeutics, and Fairmount Funds sits behind both the Paragon relationship and the Series A Preferred position. Paragon milestone economics and Fairmount's disclosed holdings are the same set of filings a reader should watch.
• Chart discontinuity. Price history before the November 2023 name change belongs to Aeglea BioTherapeutics. Long-run charts and pre-2024 highs describe a different company.